SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

ELDN Presents BESTOW Results

Eledon presents long-term extension phase 2 BESTOW results showing sustained higher kidney function and improved patient-reported outcomes with Tegoprubart compared with Tacrolimus

ELDN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.